Shares of Can Fite Biopharma Ltd (NASDAQ:CANF) have received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Brokers have set a 12 month consensus target price of $7.50 for the company and are predicting that the company will post ($0.14) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Can Fite Biopharma an industry rank of 88 out of 265 based on the ratings given to related companies.

A number of analysts have issued reports on the company. Maxim Group assumed coverage on Can Fite Biopharma in a research note on Friday, August 11th. They issued a “buy” rating and a $7.00 price target on the stock. HC Wainwright set a $6.00 price target on Can Fite Biopharma and gave the stock a “buy” rating in a research report on Thursday, August 10th.

Shares of Can Fite Biopharma (NASDAQ:CANF) traded up 1.16% during midday trading on Friday, reaching $1.74. 16,739 shares of the company’s stock traded hands. The company’s market capitalization is $30.21 million. The stock’s 50 day moving average is $1.67 and its 200-day moving average is $1.81. Can Fite Biopharma has a 52 week low of $1.50 and a 52 week high of $2.82.

COPYRIGHT VIOLATION WARNING: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/16/can-fite-biopharma-ltd-canf-receives-average-rating-of-strong-buy-from-brokerages.html.

About Can Fite Biopharma

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

Get a free copy of the Zacks research report on Can Fite Biopharma (CANF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related companies with MarketBeat.com's FREE daily email newsletter.